Talis Biomedical Corporation

TLIS

US87424L2079

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 04:30:00 2024-04-24 pm EDT			5-day change	1st Jan Change
9.2 ^USD	+2.11%		+8.88%	+23.49%

Apr. 02	North American Morning Briefing : Stocks Seen -2-	DJ
Mar. 28	Talis Biomedical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Talis: Q2 Earnings Snapshot

August 02, 2022 at 04:57 pm EDT

MENLO PARK, Calif. (AP) _ Talis Biomedical Corp. (TLIS) on Tuesday reported a loss of $27 million in its second quarter.

The Menlo Park, California-based company said it had a loss of $1.01 per share.

The infectious disease diagnostics company posted revenue of $572,000 in the period.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on TLIS at https://www.zacks.com/ap/TLIS

Latest news about Talis Biomedical Corporation

North American Morning Briefing : Stocks Seen -2-	Apr. 02	DJ
Talis Biomedical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
North American Morning Briefing : Stock Futures Muted; Nvidia Slips in Offhours Trading	Nov. 22	DJ
Talis Biomedical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Talis Biomedical Announces Exploration of Strategic Alternatives	Nov. 13	CI
Talis Biomedical Corporation Announces Resignation of Melissa Gilliam from its Board of Directors, as Member of Nominating and Corporate Governance Committee and as Member and Co-Chairperson of Science, Technology and Clinical Affairs Committee	23-09-01	CI
BTIG Adjusts Talis Biomedical's Price Target to $5 From $5.25, Keeps Sell Rating	23-08-16	MT
Talis Biomedical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Transcript : Talis Biomedical Corporation, Q2 2023 Earnings Call, Aug 10, 2023	23-08-10
Talis Biomedical Corporation Announces Resignation of Andrew A. Lukowiak as President and Chief Scientific Officer	23-08-02	CI
Talis Biomedical Corporation Announces New Data Supporting the Development of Its Planned CT/NG/TV and Vinal Infections Panels	23-07-27	CI
Talis Biomedical Appoints Former Roche Molecular CEO Heiner Dreismann to Board of Directors	23-05-23	CI
Talis Biomedical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Transcript : Talis Biomedical Corporation, Q1 2023 Earnings Call, May 11, 2023	23-05-11
Talis Biomedical Corporation Appoints Kimberly Popovits as Lead Independent Director	23-05-08	CI
Talis Biomedical Corporation Announces Executive Changes	23-04-11	CI
Earnings Flash (TLIS) TALIS BIOMEDICAL CORPORATION Reports Q4 Revenue $0.3M	23-03-22	MT
North American Morning Briefing : Stock Futures -2-	23-03-21	DJ
Talis Biomedical Corporation Announces Resignation of Felix Baker from the Board of Directors	23-03-10	CI
Talis Biomedical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-03	CI
Earnings Flash (TLIS) TALIS BIOMEDICAL CORPORATION Posts Q3 Revenue $796,000	22-11-03	MT
Talis Biomedical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-02	CI
Transcript : Talis Biomedical Corporation, Q2 2022 Earnings Call, Aug 02, 2022	22-08-02
Earnings Flash (TLIS) TALIS BIOMEDICAL CORPORATION Posts Q2 Revenue $0.6M	22-08-02	MT
Talis Biomedical Corporation(NasdaqGM:TLIS) dropped from S&P Global BMI Index	22-06-20	CI

Chart Talis Biomedical Corporation

Duration

Period

More charts

Talis Biomedical Corporation is engaged in transforming diagnostic testing by developing and commercializing products that are designed to enable molecular testing for infectious diseases and other conditions at the point of care. The Company is engaged in developing the Talis One system, a cloud-enabled molecular diagnostic platform. The Talis One system consists of compact instrument, single-use test cartridges and software that is designed to support a central cloud database, which work together and are designed to provide central laboratory levels of accuracy and be operated by an untrained user. It is also focused on developing Talis One assay kits for respiratory infections, and infections related to women's health and sexually transmitted infections (STIs). It is also developing influenza A and influenza B tests to be included as part of a respiratory panel with its COVID-19 assay (Respiratory Panel), as well as exploring adding a respiratory syncytial virus (RSV) test.

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - Q1 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
TALIS BIOMEDICAL CORPORATION	+23.49%	16.76M
IQVIA HOLDINGS INC.	+1.56%	43.84B
MODERNA, INC.	+5.73%	41.68B
LONZA GROUP AG	+44.87%	41.25B
CELLTRION, INC.	-10.92%	27.04B
ICON PUBLIC LIMITED COMPANY	+7.56%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-25.27%	18.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.01%	12.29B
MEDPACE HOLDINGS, INC.	+26.06%	12.29B
UNITED THERAPEUTICS CORPORATION	+6.84%	11.15B

Other Biotechnology & Medical Research

Talis Biomedical Corporation

Equities

TLIS

US87424L2079

Biotechnology & Medical Research

Talis: Q2 Earnings Snapshot

Latest news about Talis Biomedical Corporation

Chart Talis Biomedical Corporation

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research